الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 82 |  |  |
| | | from | 82 | | |
Abstract
Psoriasis is a chronic T-cell-driven inflammatory skin disease affecting about 2%-3% of the population worldwide. It’s characterized by hyperproliferation of basal epidermal cells and aberrant terminal differentiation. In psoriatic skin, epidermal turnover time is markedly diminished and keratinization is accelerated, with hyperplasia of the spinous layer and incomplete differentiation of granular cell layers.
Cyclin-dependent kinases (CDKs) are serine-threonine protein kinases involved in the regulation of cell-cycle progression, transcriptional regulation, and several other essential biological processes.
This study aimed to assess the immunohistochemical expression of CDK2 in psoriatic skin and its relation to disease severity and activity.
The study was conducted on fifty individuals selected from the attendants of the Dermatology Outpatient Clinic of the Main University Hospital, Faculty of Medicine, University of Alexandria. Thirty psoriasis patients and twenty normal age and sex-matched persons, serving as the control group were recruited.
The present study had revealed the following results:
There was a significant increase in stratum corneum thickness, full epidermal thickness, the presence of Munro’s micro abscess, parakeraosis, dermal papillae thickness, and dermal inflammation in lesional skin compared to perilesional skin and the control group.
Whereas CDK2 immunostaining showed only few positive nuclei in basal keratinocytes in normal control. No positive cells were seen in suprabasal keratinocytes. Meanwhile, psoriatic group showed diffuse nuclear positivity in suprabasal keratinocyte.
Also there was a statistically significant difference in CDK2 immune percentage between the lesional and perilesional skin and this was positively correlated with disease severity.
NO statistically significant correlation was found between CDK2 Immune percentage and histopathological findings.
In conclusion CDK2 may play a role in the development of psoriasis and may be a potential therapeutic target.